La cadena de opciones muestra datos clave de las opciones de acciones de Neurocrine Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Neurocrine Biosciences..

Neurocrine Biosciences (NASDAQ:NBIX) Bolsa, Cadena de Opciones

Neurocrine Biosciences

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences Inc

In the last three months, 7 analysts have published ratings on Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.43, a high estimate of $190.00, and a low estimate of $148.00. Observing a 4.77% increase, the current average has risen from the previous average price target of $161.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1738706415_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Neurocrine Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$176.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$162.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$148.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Neurocrine Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>About Neurocrine Biosciences</h2>
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
<h3>Neurocrine Biosciences: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Neurocrine Biosciences's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 24.72%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's net margin is impressive, surpassing industry averages. With a net margin of 20.86%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.97% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.8% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

NBIX

Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and raises the price target from $170 to $185.

News

Price Target

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $185

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $162 to $176.

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $176

On Monday, Neurocrine Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43251057/neurocrine-biosciences-announces-amendment-to-strategic-collaboration-with-takeda-to-develop-and-c" rel="noreferrer noopener">amended its agreement</a> with Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) to develop and commercialize osavampator (NBI-1065845/TAK-653).
Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except&nbsp;Japan, where Takeda will reacquire exclusive rights.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42508449/neurocrines-drug-gains-fda-nod-as-first-targeted-cah-treatment-analyst-highlights-blockbuster-potential" rel="noreferrer noopener">Neurocrine&#8217;s Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential</a>
Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments.
&#8220;With the recent successful completion of our End-of-Phase 2 meeting with FDA for osavampator, we look forward to beginning the Phase 3 program in the first half of this year,&#8221; said Kyle Gano, Chief Executive Officer at Neurocrine Biosciences.
In 2020,&nbsp;Neurocrine Biosciences&nbsp;and Takeda entered into a strategic collaboration to develop and commercialize compounds in depression and schizophrenia, including an exclusive license to both osavampator and NBI-1070770, which are being studied for the treatment of major depressive disorder, as well as a preclinical GPR139 antagonist development program.
Concurrently, Neurocrine Biosciences initiated a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator as an adjunctive treatment to antidepressants for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43266015/neurocrine-biosciences-announces-initiation-of-phase-3-registrational-program-for-osavampator-as-a" rel="noreferrer noopener">major depressive disorder</a>.
In&nbsp;April 2024, Neurocrine announced topline data for its Phase 2 SAVITRI study in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38386407/neurocrine-biosciences-says-treatment-can-alleviate-several-symptoms-associated-with-depressive-d" rel="noreferrer noopener">adult subjects with MDD</a>.
The study met its primary and&nbsp;key&nbsp;secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Åsberg Depression Rating Scale (MADRS) total score at both Day 28 (primary) and Day 56 (secondary).&nbsp;
Price Action: NBIX stock is up 1.38% at $150.23 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43249153/mattel-partners-with-ferrari-for-hot-wheels-product-line-after-a-decade" target="_blank" rel="noreferrer noopener">Mattel Partners With Ferrari For First Hot Wheels Product Line In A Decade</a></li>
</ul>

Biotech

Large Cap

Health Care

Contracts

Movers

General

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Neurocrine Biosciences Initiates Phase 3 Registrational Program For Osavampator As Adjunctive Therapy For Treatment Of Major Depressive Disorder In Adults

Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. 
Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments.

Neurocrine Biosciences Amends Agreement With Takeda To Develop, Commercialize Osavampator; Takeda Reacquires Rights To Osavampator In Japan

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4342843-1&amp;h=3800559142&amp;u=http%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology &amp; Metabolism (JCEM), sponsored by the company. The supplement, titled "<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4342843-1&amp;h=1522570349&amp;u=https%3A%2F%2Facademic.oup.com%2Fjcem%2Fissue%2F110%2FSupplement_1&amp;a=Challenges+and+Opportunities+in+the+Management+of+Classic+Congenital+Adrenal+Hyperplasia+Due+to+21-Hydroxylase+Deficiency+Throughout+the+Lifetime">Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime</a>," contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges faced by individuals with classic CAH. JCEM is a leader in disseminating research that supports healthcare providers, patients and caregivers in advancing the understanding and management of various endocrinology conditions, such as CAH.

Neurocrine Announced Publication Of Supplement On Classic Congenital Adrenal Hyperplasia In The Journal Of Clinical Endocrinology & Metabolism, Covering Clinical, Psychosocial, Treatment Challenge

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $142 to $162.

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $162

<ul>
<li>Narrative Review Assesses Current Treatment Challenges and the Evolving Classic Congenital Adrenal Hyperplasia (CAH) Therapeutic Landscape
<ul>
<li>Non-Glucocorticoid (GC) Mechanisms for Treatment of CAH Could Enable Control of Excess ACTH and Androgens Without the Need for High-Dose GCs, Reducing Related Complications Over a Lifetime</li>
</ul>
</li>
</ul>

Neurocrine Biosciences Publishes Narrative Review Discussing Challenges Of Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia

Piper Sandler analyst David Amsellem reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and maintains $160 price target.

Reiteration

Piper Sandler Reiterates Overweight on Neurocrine Biosciences, Maintains $160 Price Target

Barclays analyst Carter Gould maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and raises the price target from $160 to $165.

Barclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $165

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) stock escalated 33.88% after the company and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced that primary endpoints were met in the Phase 2b trial of Duvakitug for <a href="https://www.benzinga.com//node/42531132" target="_blank" rel="noreferrer noopener">ulcerative colitis and Crohn&#8217;s disease</a>.</li>
<li>Klaviyo, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) shares surged 12.85%.</li>
<li>Olive Garden parent Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) stock rose 12.54% after the company reported better-than-expected second-quarter EPS and <a href="https://www.benzinga.com//node/42585797" target="_blank" rel="noreferrer noopener">issued an FY25 revenue outlook</a>. Several analysts raised the <a href="https://www.benzinga.com/quote/dri/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares upped 10.91%. Stephens &amp; Co. initiated coverage with an Equal-Weight rating and <a href="https://www.benzinga.com/quote/docs/analyst-ratings" target="_blank" rel="noreferrer noopener">a price forecast of $55</a>.</li>
<li>Birkenstock Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) shares increased 9.70% after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance. Several analysts raised <a href="https://www.benzinga.com//node/42599431" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) stock upped 7.30% after the company reported better-than-expected <a href="https://www.benzinga.com//node/42553094" target="_blank" rel="noreferrer noopener">first-quarter EPS and revenues</a>. Several analysts raised <a href="https://www.benzinga.com/quote/jbl/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) stock rose 6.88%. The FDA approved Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with <a href="https://www.benzinga.com//node/42508449" target="_blank" rel="noreferrer noopener">classic congenital adrenal hyperplasia (CAH).</a></li>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock was up 6.54% last week, continuing strength from Q3 earnings.</li>
<li>Dr. Reddy&#8217;s Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) stock increased 6.29%.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) shares upped 6.13% last week.</li>
</ol>
Photo by Sundry Photography via Shutterstock

Trading Ideas

BIRK

CHWY

DOCS

KVYO

TEVA

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

7 analysts have expressed a variety of opinions on Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $151.86, a high estimate of $190.00, and a low estimate of $114.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.5%. 
<img src="https://www.benzinga.com/files/images/story/2024/1734721222_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Neurocrine Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$148.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$114.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$155.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$133.00</td>
<td>$136.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Neurocrine Biosciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Discovering Neurocrine Biosciences: A Closer Look</h2>
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
<h3>Financial Milestones: Neurocrine Biosciences's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Neurocrine Biosciences displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 24.72%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.86% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.97%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.8%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Neurocrine Biosciences Stock

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) from Hold to Hold.

Needham Reiterates Hold on Neurocrine Biosciencesto Hold

WIIM

Neurocrine Biosciences shares are trading higher. Wedbush reiterated its Outperform rating on the stock and maintained its $148 price target.

On Friday, the FDA approved Neurocrine Biosciences, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) Crenessity (crinecerfont)&nbsp;capsules and oral solution as&nbsp;an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42494466/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatmen" rel="noreferrer noopener">congenital adrenal hyperplasia (CAH).</a>
CAH is&nbsp;a rare, inherited disorder that affects the adrenal glands and causes them to be larger than normal.&nbsp;The adrenal glands are located above the kidneys and produce hormones that regulate blood sugar, blood pressure, and other bodily functions.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40857425/neurocrine-shifts-focus-to-new-schizophrenia-treatment-after-luvadaxistat-trial-mis" rel="noreferrer noopener">Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint</a>
Crenessity, a potent and selective oral corticotropin-releasing factor type 1 receptor antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone and downstream adrenal androgen production, allowing for glucocorticoid dose reduction.
Crenessity is expected to be commercially available in approximately one week. To centralize and simplify prescription fulfillment, the medication will be provided through PANTHERx Rare, a specialty pharmacy.
William Blair sees significant potential in the CAH market but acknowledges that for this to be a blockbuster $1 billion-plus commercial opportunity, there will need to be both patient and clinician education that supraphysiological (amounts greater than normally found in the body) glucocorticoid dosing would no longer be the only way to control androgen levels and prevent adrenal crises.
The analyst writes that focusing on educational initiatives and collaborating with patient advocacy groups, such as the CARES Foundation, is a smart move as Neurocrine prepares for its product launch.
While early-stage competitors like Crinetics Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) show promising data, Neurocrine&#8217;s position as the first to market in treating congenital adrenal hyperplasia gives it a strong advantage.
Although investors have mixed opinions about the potential success of crinecerfont, William Blair sees opportunities for it to become a blockbuster drug alongside Ingrezza in the long run.
The analyst maintains the <a target="_blank" href="https://www.benzinga.com/quote/NBIX/analyst-ratings" rel="noreferrer noopener">Outperform rating on Neurocrine.</a>
Price Action: NBIX stock is up 2.80% at $130.25 premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42490072/solid-biosciences-positioned-for-next-gen-duchenne-muscular-dystrophy-treatment-success-analyst" target="_blank" rel="noreferrer noopener">Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

CRNX

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

Wedbush analyst Laura Chico reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and maintains $148 price target.

Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $190 price target.

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $190 Price Target

<ul>
<li>CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach
<ul>
<li>FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAHCRENESSITY is expected to be commercially available in approximately one week Rare Pediatric Disease Priority Review Voucher granted in connection with approval</li>
</ul>
</li>
</ul>

Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="583" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092632/Black-Friday-Bargains-1024x583.jpg" alt="" class="wp-image-3701" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092632/Black-Friday-Bargains-1024x583.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092632/Black-Friday-Bargains-300x171.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092632/Black-Friday-Bargains-768x437.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092632/Black-Friday-Bargains.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Screening For Bargains On Black Friday</h2>
Since American retailers traditionally offer deals on the day after Thanksgiving (&#8220;Black Friday&#8221;), it seemed fitting to see if the stock market was offering any too. The main metric I used to screen for deals was Chartmill&#8217;s overall valuation rating. I used that, because it incorporates several measures of valuation, including Price/Earnings (P/E), Forward P/E, Price/Book, and PEG (P/E divided growth rate). 
<h2 class="wp-block-heading">Setting Up The Screen&nbsp;</h2>
To make sure I wasn&#8217;t picking up a bunch of &#8220;cheap for a reason&#8221; stocks, I added a few other technical and fundamental metrics to the screen:
<ul>
<li>Trades in U.S.</li>
<li>Has options.&nbsp;</li>
<li>Valuation rating &gt;=7.&nbsp;</li>
<li>Technical rating &gt;=6</li>
<li>Set-up rating &gt;=6</li>
<li>Growth rating &gt;=6</li>
<li>Profitability rating &gt;=6</li>
<li><a href="https://www.investopedia.com/terms/p/piotroski-score.asp" target="_blank" rel="noreferrer noopener">Piotroski F-Score</a> >=8</li>
</ul>
The technical and valuation ratings are self-explanatory; the set-up rating measures the short-term consolidation of share prices. Each of those ratings is on a scale of 0 to 10, with 10 being best; the Piotroski F-Score is on a scale from 0 to 9, with 9 being best.&nbsp;
<h2 class="wp-block-heading">The Results&nbsp;</h2>
That screen yielded these four names:&nbsp;
<ul>
<li>Neurocrine Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)</li>
<li>United Therapeutics Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</li>
<li>Supernous Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>)</li>
<li>Expedia Group, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)</li>
</ul>
<h2 class="wp-block-heading">Are These Stocks Worth Buying Now?&nbsp;</h2>
Maybe, but they&#8217;re probably not the best stocks to buy now. The best stocks typically aren&#8217;t cheap. In <a href="https://www.zerohedge.com/news/2024-11-20/post-just-saved-us-money-nvidia" target="_blank" rel="noreferrer noopener nofollow">a recent post</a> (&#8220;The Post That Just Saved Us Money On Nvidia&#8221;), I mentioned that I&#8217;d consider placing a bullish options trade on Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) again when it had a valuation rating of 6. I didn&#8217;t say a valuation rating of 7, because as long as the AI story continues, I don&#8217;t expect Nvidia to trade that cheaply. It may not even trade at a valuation rating of 6 in the near future, outside of a major market correction. Maybe it&#8217;s not worth waiting for one. 
<h2 class="wp-block-heading">The Valuation Ratings Of Portfolio Armor&#8217;s Top Ten Names</h2>
On Wednesday, I posted Portfolio Armor&#8217;s top ten names. Those are the ones are system estimates will have the highest returns over the next six months, net of hedging costs.
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/top-names-11272024"><img loading="lazy" decoding="async" width="917" height="813" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092723/Top-Names-Wednesday.jpg" alt="" class="wp-image-3702" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092723/Top-Names-Wednesday.jpg 917w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092723/Top-Names-Wednesday-300x266.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092723/Top-Names-Wednesday-768x681.jpg 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
Occasionally, we see some inexpensive stocks on that list (valuation ratings of 7 or so), but this week. The average valuation rating of the stocks in Wednesday&#8217;s top ten was 2.7. The overall top name,&nbsp;Tesla, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), had a valuation rating of 4.&nbsp;
<h2 class="wp-block-heading">The Limits Of Valuation </h2>
If you think about Tesla&#8217;s Optimus robots, you get a sense of the limitations of valuation in selecting stocks.
<figure class="wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Tesla Optimus Robot Explained" width="500" height="281" src="https://www.youtube.com/embed/1t1KMXSBrBM?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
The robots aren&#8217;t for sale to the general public yet, so they don&#8217;t appear in any of the metrics that comprise Tesla&#8217;s valuation rating. But Tesla CEO Elon Musk says they&#8217;ll be the most popular product in the world. If he&#8217;s right, Tesla shares will be worth a lot more in the future.&nbsp;
Deciding whether Elon is likely to be right about those robots may turn out to be a more profitable exercise for investors than crunching valuation numbers. Our system defers to the wisdom of crowds on that&#8211;the crowd of stock investors, and the crowd of options traders. Its gauges of share price movement and options sentiment suggest it makes sense to bet on Tesla now.&nbsp;
Would you like a heads up when we place our next trade based on our top names? If so, you can subscribe to our trading Substack/occasional email list below.&nbsp;
Are you are concerned about market risk? You can download our optimal hedging app by clicking on the QR code below, or aiming your iPhone camera at it.
<figure class="wp-block-image size-full"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29092919/QR-Code-8.jpg" alt="" class="wp-image-3703" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names,&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29093038/Widget-8.jpg" alt="" class="wp-image-3704" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29093038/Widget-8.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/29093038/Widget-8-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></a></figure>

EXPE

NVDA

SUPN

TSLA

Screening For Black Friday Bargains In The Stock Market

Neurocrine (NBIX) initiated a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator, an investigational dru...

Neurocrine initiates Phase 3 registrational program for osavampator in MDD

Mizuho Securities analyst Uy Ear has maintained their neutral stance on NBIX stock, giving a Hold rating on January 21. Uy Ear has given his Hold r...

Cautious Outlook on Neurocrine Due to Developmental and Financial Uncertainties

UBS raised the firm's price target on Neurocrine (NBIX) to $176 from $162 and keeps a Buy rating on the shares. The firm expects Neurocrine to indi...

Neurocrine price target raised to $176 from $162 at UBS

Busy Earnings Season Continues With Alphabet, Disney, Palantir To Report Results

Wall Street Week Ahead

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) on January 31 and set a price target of $190.00. T...

Neurocrine (NBIX) Receives a Buy from Evercore ISI

Morgan Stanley analyst Jeffrey Hung has maintained their bullish stance on NBIX stock, giving a Buy rating today. Jeffrey Hung has given his Buy ra...

Neurocrine's Potential Undervalued: Buy Rating Boosted by Pipeline Advancements and Revenue Projections

BofA raised the firm's price target on Neurocrine (NBIX) to $184 from $182 and keeps a Buy rating on the shares. The firm, which highlights that th...

Neurocrine price target raised to $184 from $182 at BofA

Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval

Neurocrine Biosciences Q4 2024 Earnings Preview

ACCD

AMGN

CBOE

FCEL

GOOG

GOOGL

ICAD

IDXX

MARK

MSTR

NXPI

PLTR

PMNT

QCOM

REKR

SDST

TSX:RCT

TTAM

UBER

Press Releases

Neurocrine Biosciences to Participate at Investor Conferences in December

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

Comments

Neurocrine Biosciences

Neurocrine Biosciences (NBIX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL